The meaning of our low-titre ACPA-positive individuals therefore remains uncertain, and further follow up is needed to ascertain whether these ACPA-positive individuals may eventually go on to develop RA and how their ACPA titre varies over time. This evidence concerns the gene PRTN3 and rheumatoid arthritis.